Peter Konrad, MD, presents exciting findings that show Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) in early stage Parkinson’s Disease may slow tremor progress at the Congress of Neurological Surgeon’s (CNS) 2018 Annual Meeting, on Wednesday, October 10, in the General Scientific Session. “DBS is the first therapy to show disease modifying effect—it can actually slow down cardinal features of Parkinson’s. There has been no therapy, drug or device
In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson’s disease psychosis (PDP) — a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions — researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin (marketed
While about 11 percent of children (4-17 years old) nationwide have been diagnosed with attention-deficit hyperactivity disorder (ADHD), the long-term health effects of having ADHD and of common ADHD medications remains understudied. Researchers at University of Utah Health found that ADHD patients had an increased risk of developing Parkinson’s and Parkinson-like diseases than individuals with no ADHD history. The results are available online on September 12 in the journal Neuropsychopharmacology.
Electrical stimulation of the brain and spinal cord may help treat the symptoms of rare movement disorders called neurodegenerative ataxias, according to a study published in the August 22, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology. There are several types of these disorders, which can be hereditary or occur randomly, including spinocerebellar ataxia, multiple system atrophy and Friedreich’s ataxia. Symptoms of ataxias include a lack
People who have been diagnosed with a mild concussion, or mild traumatic brain injury, may have a 56 percent increased risk of developing Parkinson’s disease, according to a study published in the April 18, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology. “Previous research has shown a strong link between moderate to severe traumatic brain injury and an increased risk of developing Parkinson’s disease
Dopamine, a signaling chemical in the brain, has the lofty job of controlling emotions, moods, movements as well as sensations of pleasure and pain. Dysfunction of this critical neurotransmitter is the cause of a number of diseases, most notably, Parkinson’s disease. Parkinson’s disease is caused by the death of dopamine-producing cells and most theories of disease risk involve the selective vulnerability of ageing dopamine neurons to genetic mutations or to
Working with lab-grown human brain cells, Johns Hopkins researchers report they have uncovered a much sought-after connection between one of the most common genetic mutations in Parkinson’s disease and the formation of fatty plaques in the brain thought to contribute to the destruction of motor neurons that characterize the disease. The mutation occurs in a gene that holds the code for GBA1, an enzyme that metabolizes fatty molecules in the
Sunovion Pharmaceuticals Inc. announced top line results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trials from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes). Study CTH-300 met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants. Apomorphine sublingual film is being